Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 72, Issue 8, 2013, Pages 1425-1427

  Manetti, Mirko ^a,b   Guiducci, Serena ^b   Romano, Eloisa ^b   Bellando Randone, Silvia ^b   Lepri, Gemma ^b   Bruni, Cosimo ^b   Conforti, Maria Letizia ^b   Ibba Manneschi, Lidia ^a   Matucci Cerinic, Marco ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TYROSINE KINASE RECEPTOR; VASCULOTROPIN 165;

ADULT; CLINICAL FEATURE; COLORIMETRY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPOXEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; QUALITY OF LIFE; RAYNAUD PHENOMENON; RNA SPLICING; SYSTEMIC SCLEROSIS;

CYTOKINES; QUALITATIVE RESEARCH; SYSTEMIC SCLEROSIS;

CAPILLARIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NAILS; PROTEIN ISOFORMS; SCLERODERMA, DIFFUSE; SCLERODERMA, LOCALIZED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880135938     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-203183     Document Type: Letter

References (10)

1. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev 2007;6:520-3. (Pubitemid 47374612)
2. Manetti M, Guiducci S, Ibba-Manneschi L, et al. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 2010;14:1241-54.
3. Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16. (Pubitemid 38931842)
4. Choi JJ, Min DJ, Cho ML, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003;30:1529-33.
5. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008;8:880-7.
6. Manetti M, Guiducci S, Ibba-Manneschi L, et al. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF165b splice variant. Trends Cardiovasc Med 2011;21:204-10.
7. Manetti M, Guiducci S, Romano E, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011;109: e14-26.
8. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15: 202-5. (Pubitemid 18073738)
9. Manetti M, Guiducci S, Romano E, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 2012;71:1064-72.
10. Cutolo M, Sulli A, Pizzorni C, et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27: 155-60. (Pubitemid 30058643)